Radiation Therapy for Metastatic Cancer
Recruiting in Palo Alto (17 mi)
+6 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Memorial Sloan Kettering Cancer Center
Must not be taking: Corticosteroids, Antineoplastics
Disqualifiers: Pregnancy, Uncontrolled infection, others
No Placebo Group
Trial Summary
What is the purpose of this trial?The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).
Will I have to stop taking my current medications?
You may need to stop taking certain medications. If you are on high doses of steroids, you must stop them during the study. Also, any cancer treatments should be paused for a few days before and after the radiation therapy.
What data supports the effectiveness of the treatment Lattice Radiation Therapy (LRT) and Stereotactic Ablative Radiotherapy (SABR) for metastatic cancer?
Research shows that Stereotactic Ablative Radiotherapy (SABR) is effective in treating early-stage non-small cell lung cancer and pulmonary metastases, improving tumor control and overall survival. This suggests that SABR, a component of Lattice Radiation Therapy, may also be beneficial for metastatic cancer.
12345Is stereotactic ablative radiotherapy (SABR) generally safe for humans?
Stereotactic ablative radiotherapy (SABR) is generally considered safe for treating various cancers, but it can cause serious complications, especially if not carefully planned and guided. Studies have shown it to be a safe option for liver and lung tumors, but there are risks of toxic effects, including potential damage to nearby organs.
26789How is Lattice Radiation Therapy different from other treatments for metastatic cancer?
Lattice Radiation Therapy (LRT) is unique because it combines high doses of radiation delivered precisely to cancerous areas, similar to Stereotactic Body Radiation Therapy (SBRT), which is already used for early-stage lung cancer and other conditions. This precise targeting allows for effective treatment of tumors while minimizing damage to surrounding healthy tissue, making it a promising option for patients with metastatic cancer.
1241011Eligibility Criteria
This trial is for adults with advanced solid tumors needing palliative radiation, who have at least one other site of metastasis suitable for radiation. They must be in good physical condition (ECOG 0 or 1) and understand the study's risks. It's not for those previously radiated at the same sites, with uncontrolled conditions like infections or diabetes, on steroids, pregnant/breastfeeding, having a second active cancer, or unable to follow study procedures.Inclusion Criteria
I have an advanced cancer that needs radiation therapy for symptom relief.
I have cancer that has spread to at least one other part of my body outside the brain.
I am 18 years old or older.
+1 more
Exclusion Criteria
Patients who are pregnant or breastfeeding
I understand the study's purpose and risks and can give informed consent.
I am willing and able to follow all study requirements.
+5 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Radiation
Participants receive lattice radiation therapy (LRT) or standard stereotactic body radiation therapy (SBRT) to treat metastatic solid tumors
6-8 weeks
Follow-up
Participants are monitored for safety and effectiveness after radiation therapy, with a focus on immune cell infiltration and overall response rate
12 weeks
Standard-of-care response assessment CT or F-18-FDG PET/CT scan
Participant Groups
The trial compares two types of radiation therapy: Lattice Radiation Therapy (LRT) and standard Stereotactic Body Radiation Therapy (SBRT). The goal is to see which method is more effective and how they influence immune cells' ability to attack tumor cells.
1Treatment groups
Experimental Treatment
Group I: Participants with metastatic solid tumorsExperimental Treatment2 Interventions
Participants will have metastatic solid tumors and at least two sites of measurable extra-cranial disease
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, NJ
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, NY
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, NJ
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)Commack, NY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
Varian Medical SystemsIndustry Sponsor
References
Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. [2020]Stereotactic ablative body radiotherapy (SABR) is an emerging noninvasive approach for the treatment of oligometastases. Limited prospective evidence is available in breast cancer.
A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer. [2022]Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy (RT) technique where high doses of radiation are precisely delivered to an extracranial target within the body, using either a single fraction of RT or using multiple small numbers of fractions. SABR has now become the standard of care treatment for patients with early-stage non-small-cell lung cancer (NSCLC) for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early-stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or RT, and future potential drug combinations with SABR.
Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer. [2013]Stereotactic ablative radiotherapy (SABR), otherwise known as stereotactic body radiation therapy (SBRT), is an external beam treatment modality that offers the ability to deliver with high precision large doses of radiation over a limited number of fractions. SABR is currently a standard of care in the treatment of early-stage primary non-small cell lung cancers (NSCLCs) that are medically inoperable and for metastases in many anatomical locations. To date, local control and toxicity parameters with SABR for early-stage NSCLCs are comparable to those found in reports of experiences with surgical resection. It is increasingly apparent that some patients with borderline resectable lung primaries are also looking to SABR as a noninvasive means of therapy. However, randomized comparisons have not been completed to assess survival in operable patients. This review summarizes the advanced technology and radiation concepts that have helped clinicians optimize the use of stereotactic ablative therapies for lung cancer, with an emphasis on the rationale for future continued use of this advanced treatment modality.
Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. [2021]Stereotactic ablative radiation therapy (SABR) is an emerging treatment option for patients with pulmonary metastases; identifying patients who would benefit from SABR can improve outcomes.
Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours. [2022]Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. The current evidence base for SABR for the treatment of primary and secondary lung tumours is appraised, and key ongoing trials are identified.
Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. [2018]The clinical applications of stereotactic body radiotherapy or stereotactic ablative radiotherapy (SABR) for the treatment of primary and metastatic tumours of different organ sites have been expanding rapidly in the recent decade. SABR requires advanced technology in radiotherapy planning and image guidance to deliver a highly conformal ablative dose precisely to targets (or tumours) in the body. Although this treatment modality has shown promising results with regard to tumour control, some serious complications have been observed and reported. In order to achieve a favourable therapeutic ratio, strategies to mitigate the risk of complications must be in place. This overview will summarise the reported serious complications caused by SABR and strategies to mitigate the risk will be discussed.
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). [2023]Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for primary renal cell carcinoma, for which long-term data are awaited. The primary aim of this study was to report on long-term efficacy and safety of SABR for localised renal cell carcinoma.
Image-guided stereotactic ablative radiotherapy for the liver: a safe and effective treatment. [2015]Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for inoperable patients or patients with irresectable liver tumors. Outcome and toxicity were evaluated retrospectively in this single-institution patient cohort.
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. [2023]Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small tumors up to 10 cm3 in volume can be well controlled with a biologically effective dose less than 100 Gy.
Undetected lymph node metastases in presumed early stage NSCLC SABR patients. [2017]Stereotactic body radiation therapy (SBRT, also called stereotactic ablative body radiation SABR) is the treatment of choice for many patients with early-stage non-small cell lung cancer (NSCLC), including those who are unfit for surgery or refuse surgery.
Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. [2023]Stereotactic ablative body radiotherapy (SABR) is one of the treatment options for oligometastatic renal cell carcinoma (RCC) but is limited by a lack of data to evaluate high-dose SABR to all/multiple sites.